153 related articles for article (PubMed ID: 11074364)
1. Germ therapy with IL-10 to treat inflammatory bowel diseases.
Michie C
Mol Med Today; 2000 Nov; 6(11):416. PubMed ID: 11074364
[No Abstract] [Full Text] [Related]
2. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
[TBL] [Abstract][Full Text] [Related]
3. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
Steidler L; Hans W; Schotte L; Neirynck S; Obermeier F; Falk W; Fiers W; Remaut E
Science; 2000 Aug; 289(5483):1352-5. PubMed ID: 10958782
[TBL] [Abstract][Full Text] [Related]
4. Delivery of therapeutic proteins through Lactococcus lactis.
Neirynck S; Steidler L
Biotechnol Genet Eng Rev; 2006; 22():253-66. PubMed ID: 18476334
[No Abstract] [Full Text] [Related]
5. Immunology. Therapeutic manipulation of gut flora.
Shanahan F
Science; 2000 Aug; 289(5483):1311-2. PubMed ID: 10979858
[TBL] [Abstract][Full Text] [Related]
6. Actobiotics as a novel method for cytokine delivery.
Steidler L; Rottiers P; Coulie B
Ann N Y Acad Sci; 2009 Dec; 1182():135-45. PubMed ID: 20074282
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
8. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces.
Benbouziane B; Ribelles P; Aubry C; Martin R; Kharrat P; Riazi A; Langella P; Bermúdez-Humarán LG
J Biotechnol; 2013 Oct; 168(2):120-9. PubMed ID: 23664884
[TBL] [Abstract][Full Text] [Related]
9. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis.
Rottiers P; De Smedt T; Steidler L
Int Rev Immunol; 2009; 28(6):465-86. PubMed ID: 19954359
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory properties of fermented soy milk with Lactococcus lactis subsp. lactis S-SU2 in murine macrophage RAW264.7 cells and DSS-induced IBD model mice.
Kawahara M; Nemoto M; Nakata T; Kondo S; Takahashi H; Kimura B; Kuda T
Int Immunopharmacol; 2015 Jun; 26(2):295-303. PubMed ID: 25887264
[TBL] [Abstract][Full Text] [Related]
11. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.
Steidler L; Neirynck S; Huyghebaert N; Snoeck V; Vermeire A; Goddeeris B; Cox E; Remon JP; Remaut E
Nat Biotechnol; 2003 Jul; 21(7):785-9. PubMed ID: 12808464
[TBL] [Abstract][Full Text] [Related]
12. Churning out safer microbes for drug delivery.
Syvanen M
Nat Biotechnol; 2003 Jul; 21(7):758-9. PubMed ID: 12833095
[No Abstract] [Full Text] [Related]
13. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice.
Waeytens A; Ferdinande L; Neirynck S; Rottiers P; De Vos M; Steidler L; Cuvelier CA
Inflamm Bowel Dis; 2008 Apr; 14(4):471-9. PubMed ID: 18092343
[TBL] [Abstract][Full Text] [Related]
14. Adrenomedullin as a potential therapeutic agent for inflammatory bowel disease.
Ashizuka S; Inatsu H; Inagaki-Ohara K; Kita T; Kitamura K
Curr Protein Pept Sci; 2013 Jun; 14(4):246-55. PubMed ID: 23745693
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-10-based therapy for inflammatory bowel disease.
Braat H; Peppelenbosch MP; Hommes DW
Expert Opin Biol Ther; 2003 Aug; 3(5):725-31. PubMed ID: 12880373
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis using a murine model of Crohn's disease.
del Carmen S; de Moreno de LeBlanc A; Perdigon G; Bastos Pereira V; Miyoshi A; Azevedo V; LeBlanc JG
J Mol Microbiol Biotechnol; 2011; 21(3-4):138-46. PubMed ID: 22286041
[TBL] [Abstract][Full Text] [Related]
17. Lactococcus lactis, a tool for the delivery of therapeutic proteins treatment of IBD.
Steidler L
ScientificWorldJournal; 2001 May; 1():216-7. PubMed ID: 12805677
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic implications of interleukin-10 in inflammatory bowel disease.
Shirachi A
Kurume Med J; 1998; 45(1):63-7. PubMed ID: 9658753
[TBL] [Abstract][Full Text] [Related]
19. Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis.
Carvalho RD; Breyner N; Menezes-Garcia Z; Rodrigues NM; Lemos L; Maioli TU; da Gloria Souza D; Carmona D; de Faria AM; Langella P; Chatel JM; Bermúdez-Humarán LG; Figueiredo HC; Azevedo V; de Azevedo MS
Microb Cell Fact; 2017 Feb; 16(1):27. PubMed ID: 28193209
[TBL] [Abstract][Full Text] [Related]
20. Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells.
Souza BM; Preisser TM; Pereira VB; Zurita-Turk M; de Castro CP; da Cunha VP; de Oliveira RP; Gomes-Santos AC; de Faria AM; Machado DC; Chatel JM; Azevedo VA; Langella P; Miyoshi A
Microb Cell Fact; 2016 Aug; 15(1):150. PubMed ID: 27576902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
